Axial VC

Aperiam Bio utilizes advanced computer vision algorithms to identify and optimize protein structures, enhancing their performance for various applications including therapeutics and cosmetics.

Appia Bio is a biotechnology company focused on developing allogeneic cell therapies.

Adaptyv is the cloud lab for protein designers, providing automated lab services to generate experimental data for AI models in protein design.

Arda Therapeutics is focused on targeting pathogenic cells to treat chronic diseases using advanced single-cell data analysis to design therapies that specifically eliminate these cells.

Attivare Therapeutics is a pre-clinical stage biotechnology company focused on developing innovative immunotherapies to treat tumors with low immunogenicity and infectious diseases using its proprietary ATTImmune platform.

BluumBio is a biotech company that rapidly cleans soil, air and water using natural enzymes found in fungi, tropical trees, and bacteria to remove industrial chemicals from the environment.

Bristle Health offers an at-home oral health test that provides insights into oral microbiome health, helping users identify the root causes of oral health issues and offering personalized care plans.

Catena Biosciences is focused on revolutionizing antibody-drug conjugates (ADCs) with its CysTyr™ Conjugation Platform, enabling the creation of Multi-Payload Conjugates (MPCs) that deliver dual payloads for treating solid tumors.

CHARM Therapeutics is pioneering a new generation of menin inhibitors for the treatment of Acute Myeloid Leukemia (AML), focusing on overcoming resistance mutations and improving efficacy and safety profiles.

ZymeCO creates advanced bio-solutions inspired by nature’s recyclers, transforming organic matter into rich soil and boosting plant growth for sustainable agriculture and turf management.

Concerto Biosciences is focused on creating safe, effective microbial products for human health, leveraging deep ecological insights and advanced AI technologies to develop innovative solutions for skincare, chronic diseases, and nutrition.

Deciduous Therapeutics aims to positively impact human health span through the development of novel medicines that activate the endogenous immune mechanism responsible for the elimination of senescent cells.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Founded in 2002, +ND invests in disruptive technologies spanning life, physical, and data sciences, prioritizing opportunities driven by scientific convergence.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).